Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform

Antibody Therapeutics · Published 2024-10-08 · DOI 10.1093/abt/tbae027

Authors being retrieved — see the publisher record. https://doi.org/10.1093/abt/tbae027

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2024

Related articles

• JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy · mAbs · 2026 · Cites or is cited by this article
• The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates · Antibody Therapeutics · 2026 · Same journal
• Beyond Affinity: AI-Supported Developability Assessment and Multi-Objective Optimization in Antibody Development · Antibody Therapeutics · 2026 · Same journal
• Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF-PD-1 antibody ivonescimab · Antibody Therapeutics · 2026 · Same journal
• Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression · Antibody Therapeutics · 2026 · Same journal
• Delivery devices and container closure systems for co-formulated and co-administered biologics · Antibody Therapeutics · 2026 · Same journal
• Integrative and Emerging Models in Antibody Research: A Comprehensive Review · Antibody Therapeutics · 2025 · Same journal
• Hinge Region Cys-to-Ser Mutation Enables Homogeneous DAR6 Anti-c-Met Biparatopic ADCs with Tolerable O-Glycosylation · Antibody Therapeutics · 2026 · Same journal
• Why antibody isotype matters for immunotherapy · Antibody Therapeutics · 2026 · Same journal
• Design and Therapeutic Rationale of Antibody-Peptide Conjugates: Insights from Maridebart Cafraglutide (AMG133) and Emerging Applications · Antibody Therapeutics · 2025 · Same journal